Neurocrine Biosciences Inc NBIX
$156.22 $0.98 (0.62%) 1D
Last Updated: Sep 11, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
Open navigation menu
Invest
Invest on your own
We do it for you
Halal tools
Screeners
Your portfolio
Calculators
Shariah
Our certifications
Learn
Education
Get help
Pricing
Company
About Musaffa
Investors
Build with us
Is Neurocrine Biosciences Inc Stock Halal?
Shariah Compliance Analysis of NBIX Stock
United States Health Care Large Cap Yes. As of September 2026, Neurocrine Biosciences Inc (NBIX) is classified as HALAL by Musaffa under its AAOIFI-based Shariah screening methodology. Neurocrine Biosciences Inc passes Musaffa's business and financial screening criteria.
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company is headquartered in San Diego, California and currently employs 2,000 full-time employees. The firm is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa, and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
NBIX Shariah Compliance
Screening Methodology: AAOIFI
As of September 2026, Neurocrine Biosciences Inc is classified as halal.
HALAL
Report Source: undefined Quarter Report
Neurocrine Biosciences Inc (NBIX) Chart
Financial Metrics & Statements of Neurocrine Biosciences Inc (NBIX)
FAQ's for Neurocrine Biosciences Inc (NBIX)
- As of September 2026, Neurocrine Biosciences Inc NBIX is classified as halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Neurocrine Biosciences Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Neurocrine Biosciences Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Neurocrine Biosciences Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Neurocrine Biosciences Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Neurocrine Biosciences Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Related Halal Stocks to Neurocrine Biosciences Inc (NBIX)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
